<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03360682</url>
  </required_header>
  <id_info>
    <org_study_id>DTG-SOT</org_study_id>
    <nct_id>NCT03360682</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients</brief_title>
  <official_title>Pilot Single‐Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV‐1‐Infected Solid Organ Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to obtain pharmacokinetic data on interactions between
      dolutegravir (DTG) and immunosuppressant drugs (Cyclosporine A, Tacrolimus, Sirolimus and
      Mycophenolic acid) in solid organ transplant (SOT) recipients to provide proof of principle
      data that DTG plus 2 nucleosides (NUCs) is safe and effective in HIV-infected SOT recipients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic study</measure>
    <time_frame>24-hours before the switch and 24-hours 2 weeks after switching</time_frame>
    <description>&quot;Peak Plasma Concentration (Cmax) mg /mL of dolutegravir.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral resistance</measure>
    <time_frame>week 48</time_frame>
    <description>number op patients with VIH viral load &gt; 50 copies/mL virological failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4+ cell</measure>
    <time_frame>week 48</time_frame>
    <description>To assess the changes in CD4+ cell count &gt;200 cel/mL in peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>week 48</time_frame>
    <description>To assess the changes in lipid profile (triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>week 48</time_frame>
    <description>To assess creatinine &gt;normal valors mg/dl&gt; 120 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: number AEs and SAEs</measure>
    <time_frame>week 48</time_frame>
    <description>number AEs and SAEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Solid Organ Transplant</condition>
  <arm_group>
    <arm_group_label>HIV-1-infected solid organ transplant patients 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.
treatment 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-1-infected solid organ transplant patients 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.
treatment 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine 300 MG</intervention_name>
    <description>Lamivudine 300 MG/day (48 weeks)</description>
    <arm_group_label>HIV-1-infected solid organ transplant patients 1</arm_group_label>
    <other_name>J05AF05</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir 600 MG</intervention_name>
    <description>Abacavir 600 MG/day (48 weeks)</description>
    <arm_group_label>HIV-1-infected solid organ transplant patients 1</arm_group_label>
    <other_name>J05AF06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 mg</intervention_name>
    <description>Dolutegravir 50 MG/day (48 weeks)</description>
    <arm_group_label>HIV-1-infected solid organ transplant patients 1</arm_group_label>
    <arm_group_label>HIV-1-infected solid organ transplant patients 2</arm_group_label>
    <other_name>J05AX12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil 245Mg Tablet</intervention_name>
    <description>Tenofovir 245 MG/day (48 weeks)</description>
    <arm_group_label>HIV-1-infected solid organ transplant patients 2</arm_group_label>
    <other_name>J05AF07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine 200 MG</intervention_name>
    <description>Emtricitabine 200 MG/day (48 weeks)</description>
    <arm_group_label>HIV-1-infected solid organ transplant patients 2</arm_group_label>
    <other_name>J05AF09</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV patients &gt;18 years old who provide signed and dated informed consent;

          2. Males and females;

          3. SOT recipients (heart, liver or kidney);

          4. On stable antiretroviral therapy (ART) for ≥6 months preceding the screening visit;

          5. Plasma HIV RNA &lt;50 cop/ml for 12 months (2 tests separated by at least 12 months with
             no viral load &gt;50 between determinations);

          6. Absence of major reverse transcriptase or integrase gene mutations affecting study
             drug efficacy by proviral DNA sequencing

        Exclusion Criteria:

          1. HIV patients who have stopped ART due to virological failure;

          2. HIV patients who require treatment with DTG contraindicated medications;

          3. History or presence of an allergy or intolerance to the study drug;

          4. Active opportunistic infection;

          5. Neoplasms requiring chemotherapy.

          6. Pregnancy or breast feeding or planned pregnancy during the study period

          7. Any other contraindication to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep M Miró Meda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico y provincial de Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Cruceta Arboles, MD</last_name>
    <phone>+34 93 2275400</phone>
    <phone_ext>4380</phone_ext>
    <email>acruceta@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico y provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Cruceta Arboles, MD</last_name>
      <phone>+34 93 2275400</phone>
      <phone_ext>4380</phone_ext>
      <email>acruceta@clinic.ub.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Ph Md</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

